Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide
Esquirol, Albert (Institut d'Investigació Biomèdica Sant Pau)
Pascual, Maria Jesus (Hospital Regional Universitario de Málaga)
García Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau)
Herruzo, Beatriz (Hospital Regional Universitario de Málaga)
Ferrá, Christelle (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Pérez, Ariadna (Hospital Clínic Universitari (València))
Torio, Alberto (Hospital Regional Universitario de Málaga)
Torrent Catarineu, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Cuesta, Marian (Hospital Regional Universitario de Málaga)
Martino Bofarull, Rodrigo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Sierra, Jorge (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Universitat Autònoma de Barcelona. Departament de Medicina

Date:	2021
Abstract:	One hundred and sixty-one patients underwent haploidentical stem cell transplantation (haploSCT) with thiotepa, busulfan, and fludarabine conditioning followed by post-transplantation cyclophosphamide (PTCy) (on days +3 and +4) and tacrolimus as graft-versus-host disease prophylaxis. Forty-two percent of patients had a high or very high revised Disease Risk Index (rDRI), 55% had an European Society for Blood and Marrow Transplantation risk score (EBMT-RS) ≥4, and 36% had an age-adjusted Hematopoietic Cell Transplant Comorbidity Index (HCT-CI-age) score ≥3. Each of these was considered an unfavorable score. Using the pretransplantation unfavorable scores that had an independent impact on each transplantation outcome studied in multivariate analysis allowed for better stratification of patient outcomes. Thus, the 3-year overall survival (OS) in patients with 0, 1, 2, and 3 unfavorable scores was 86%, 56%, 36%, and 24%, respectively. Nonrelapse mortality (NRM) was negatively impacted by the EBMT-RS and the HCT-CI-age score (3-year NRM in patients with 0, 1, and 2 unfavorable scores was 12%, 33%, and 43%, respectively), whereas the EBMT-RS and the rDRI had an impact on the 3-year relapse incidence (8%, 18%, and 41% in patients with 0, 1, and 2 unfavorable scores, respectively). In conclusion, our study shows that combining 2 or 3 of these well-defined pretransplantation scores improves the ability to predict transplantation outcomes in the setting of haploSCT with PTCy.
Grants:	Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-1395 Fundació la Marató de TV3 20133230 Generalitat de Catalunya SLT002/16/0043 Instituto de Salud Carlos III PI17/01246 Ministerio de Economía y Competitividad RD16/0011/0028
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Transplantation and cellular therapy, Vol. 27 Núm. 7 (july 2021) , p. 614.e1-614.e8, ISSN 2666-6367

DOI: 10.1016/j.jtct.2021.03.021

8 p, 1.3 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Josep Carreras Leukaemia Research Institute
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles